Omeros’ Narsoplimab Resubmission Gets Late Sept. Decision Date

Omeros Corporation said the US FDA accepted its resubmitted biologics license application for narsoplimab and set a target decision date of late September.

• Narsoplimab indicated to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy
• Company expects interactive review by US FDA
• Company sees EMA submission later this quarter

To view the source of this information, click here

To contact the reporter on this story:
Cameron Baker in Boston at cbaker225@bloomberg.net

To contact the editor responsible for this story:
Zachary Fleming at zfleming2@bloomberg.net

© 2025 Bloomberg L.P. All rights reserved. Used with permission.